Citations

Clear

941 citation(s) found for "Tan, B".

Multiple substance use and the risk of pancreatitis: a systematic review
Adeniran, Esther, Yadav, Dhiraj, Tan, Judy Y. , Lo, Simon K. , Adeniran, Esther A , Jiang, Yi, Han, Samuel , Pandol, Stephen J. , Jeon, Christie Y.

Mayo Clinic

Therapeutic Advances in Gastroenterology | August 25, 2025 | Volume: 18 | Issue: No issue available | Pages: No page available

10.1177/17562848251365030 | PMID 40873658 Get It

Background: The impact of multiple substance use on the risk of pancreatitis remains underexplored. Objective: To systematically review peer-reviewed observational studies assessing the association of multiple substance use with the risk of acute pancreatitis (AP) or chronic pancreatitis (CP) in adults. Design: We conducted a systematic review informed by the Preferred Reporting Items for Systematic Review and Meta-Analyses guideline. Data sources and methods: EMBASE, MEDLINE, and PsycINFO were searched up to March 2024. Reference lists of included studies were reviewed. From 5205 records identified, 181 relevant records were evaluated in full text. Studies evaluating the association of ⩾2 substances, including tobacco, alcohol, cannabis, and illicit substances, with AP or CP were included. Data were extracted by one reviewer, with quality control by a second reviewer. Quality assessments were independently conducted by two reviewers, with differences resolved by a third. Results: Of 11 included studies, 6 investigated AP as the outcome and 5 examined CP. Among AP studies, 5 comparing smoking and alcohol to alcohol-only use showed high heterogeneity ( I 2 = 90.9%), with relative risks (RRs) from 1.40 to 11.40. One study examining cannabis and alcohol versus alcohol found a lower risk of AP in cannabis users. Among CP studies, four comparing smoking and alcohol to alcohol-only use were heterogeneous ( I 2 = 81%) with odds ratios 1.21–31.50. Where examined, smoking increases the risk of AP and CP in a dose-dependent fashion. Heavy alcohol users demonstrated a significant increase in CP risk across all smoking categories in one study. Conclusion: Combined alcohol and tobacco use increases pancreatitis risk compared to single substance use, despite heterogeneity in RRs and exposure definitions. Evidence suggests a dose-dependent impact of smoking on pancreatitis risk when added to alcohol. Studies on the impact of a combination of other substance use on pancreatitis risk are needed. Trial registration (PROSPERO): CRD42024503677.
Quality assurance of the inter‐spot beam delivery of a dose driven continuous scanning proton therapy system
Chua, Clifford Ghee Ann , Lew, Kah Seng, Koh, Calvin Wei Yang , Wibawa, Andrew , Master, Zubin , Lee, James Cheow Lei, Beltran, Chris , Tan, Hong Qi , Beltran, Chris J , Furutani, Keith M. , Lee, Kang Hao , Park, Sung Yong

Mayo Clinic

Medical Physics | August 14, 2025 | Volume: 52 | Issue: 8 | Pages: No page available

10.1002/mp.18050 | PMID 40804772 Get It

Abstract Background Dose‐driven continuous scanning (DDCS) is a type of beam delivery in Hitachi pencil beam scanning (PBS) particle therapy system. Particle beam is irradiated continuously between spots to achieve a higher effective dose rate and a shorter beam delivery time. The beam is only turned off at break spots, the end of a treatment layer and during spill change. The break spot is a unique feature of the DDCS introduced by the treatment planning system (TPS) to interrupt continuous scanning. DDCS separates the dose delivery of a spot into a move dose and stop dose components. The move dose is controlled by the scanning speed and beam current, while the stop dose delivers the remaining monitor units (MUs). Hence, rigorous quality assurance (QA) of the scanning speed and functionality of break spot are required to ensure safe and successful DDCS delivery. Purpose We aim to report for the first time the QA methodology and result for DDCS, focusing on the scanning speed and break spot validation. Methods A rectangular spiral irradiation pattern with different degree of break spots were irradiated on a 2D strip ionization chamber (CROSSmini) detector using 50 time resolution to validate the break spots. Four methods of measuring scanning speeds were proposed. Using a spiral irradiation pattern, methods one and two applied linear regression to the scanning time measured by the CROSSmini for different inter‐spot distances, with measurements taken at sampling rates of 5 and 20 kHz, respectively. Methods three and four measured the scanning time of single inter‐spot distances in the X and Y directions. Method three measured the scanning time with the CROSSmini while method four measured the rise and fall time of the scanning magnet (SCM) current. All measurements were performed with 70.2, 150.2 and 228.7 MeV proton beam energies and three different beam currents of 8, 14 and 20 MU/s. Lastly, the scanning speed tolerance limit was calculated analytically under the requirement of avoiding a beam abort when the stop dose was less than zero. Results The data recorded by the CROSSmini under the spiral irradiation patterns with break spots was reconstructed into a 2D dose, and the break spots’ operations were visually validated for all the energies and beam currents. There were no statistically significant difference in the measured X and Y scanning speeds across the four methods. However, the last method involving the SCM current yielded the largest type A uncertainty of up to 25% () due to the noisy signal. The first method with the linear regression and 5 kHz acquisition rate was preferred due to a smaller type A uncertainty of up to 2.0% and a lower false negative rate in detecting the rising and falling edges during scanning. The calculated tolerance limit based on our current DDCS setting was found to be 0.50 times of the expected scanning speed. Conclusion We have introduced QA protocols for DDCS, designed to ensure complete and safe beam delivery without interruptions caused by move doses exceeding planned spot doses.
Genetic and Clinical Characterization of a Large Cohort with Suspected Monogenic Stone Disease
Cogal, Andrea G. , Ali, Ahmed E. , Arnous, Muhammad G. , Zhou, Le‐Ting , Arroyo, Jennifer, Seide, Barbara M., Reynolds, Laura M. , Kennedy, Gabrielle N. , Milliner, Dawn S. , Sas, David J. , Harris, Peter C. , Cheungpasitporn, Wisit , Tan-Arroyo, Jennifer , Alhadi, Abdulmueti , Arroyo, Jennifer , Seide, Barbara M , Rossler, Kalina J , Reynolds, Laura M , Kennedy, Gabrielle N , Elbarougy, Doaa E , Goldfarb, David S , Milliner, Dawn , Lieske, John C , Harris, Peter C , Cheungpasitporn, Wisit , Alhadi, Abdulmueti , Elbarougy, Doaa E. , Goldfarb, David S. , Lieske, John C.

Mayo Clinic

Clinical Journal of the American Society of Nephrology | August 12, 2025 | Volume: 20 | Issue: 12 | Pages: 1670-1682

10.2215/cjn.0000000817 | PMID 40794449 Get It

Key Points Genetic testing of individuals suspected of monogenic urinary stone disease resolved 34% of families with 22 different genes detected. Resolved individuals had a lower baseline and last visit eGFR and earlier age of stone presentation than the unresolved group. Specific phenotypes and younger diagnostic age were associated with a monogenic cause, allowing refinement of future screenings. Background Urinary stone disease with a clear genetic cause, monogenic stone disease (MSD), is increasingly recognized as a significant proportion of the total population. When MSD is suspected, genetic testing provides a firm diagnosis that can alter management and treatment. Here, we present testing results from a large cohort with suspected MSD. Methods Patients with features suggestive of MSD (early onset, family history, frequent stones, nephrocalcinosis [NC], and/or CKD) were recruited by the Rare Kidney Stone Consortium and genotyped for up to 160 known or candidate MSD genes via a targeted massively parallel sequencing panel. We compared clinical and biochemical features between genetically resolved MSD and unresolved individuals. Results Of 426 families (657 patients) enrolled, 145 (34%) were resolved with identified disease associated variants in 22 known MSD genes. Ninety-nine families were biallelic, 37 monoallelic, and two digenic. An additional 21 of the 231 screened family members were resolved. Genes identified in ten or more families include the following: AGXT , HOGA1 , SLC34A3 , CYP24A1 , SLC3A1 , and CLCN5 . Compared with the unresolved group, MSD probands had a lower baseline and last visit eGFR, earlier age of stone presentation, and more stone events and procedures/year of life. The resolve rate was higher in those <16 years, and NC was seen earlier in the MSD group. Overall, NC was a risk factor for lower eGFR. Among the specific disorders, patients with primary hyperoxaluria had the earliest age of stone and NC diagnosis, and as expected, the highest urinary oxalate level. Conclusions Our study emphasizes the value of selecting patients enriched for factors associated with MSD, and comprehensive genetic testing to achieve a high yield of genetic diagnoses. Significant clinical and biochemical characteristics of patients with MSD were defined. A definitive MSD diagnosis facilitates individualized management and strategies to delay disease progression in probands and affected family members.
Redundancy‐weighted FDK reconstruction for dual‐detector combined‐scanning CBCT: Practical implementation for image guided particle therapy
Song, Bongyong , Whitaker, Thomas J. , Gautam, Archana S., Olberg, Sven, Choi, Byongsu , Lee, Sung Uk , Jeong, Jong Hwi , Kim, Jeongheon, Tan, Jun , Lü, Bo , Yaddanapudi, Sridhar , Beltran, Chris , Park, Justin C., Tan, Jun , Furutani, Keith, Beltran, Chris J , Yaddanapudi, Sridhar , Gautam, Archana S., Liang, Xiaoying , Furutani, Keith M. , Tan, Jun

Mayo Clinic

Medical Physics | August 9, 2025 | Volume: 52 | Issue: 8 | Pages: No page available

10.1002/mp.17996 | PMID 40781831 Get It

Abstract Background Cone‐beam computed tomography (CBCT) is essential for image‐guided particle therapy (IGPT), providing daily patient positioning, anatomical monitoring, and treatment verification. However, conventional single‐detector CBCT suffers from poor soft‐tissue contrast, long acquisition times, and motion artifacts, reducing its effectiveness for adaptive radiotherapy workflows. Addressing these challenges requires an advanced CBCT reconstruction approach capable of enhancing image quality while reducing scan time and radiation exposure. Purpose This study introduces a Dual Detector Combined Scanning (DDCS) CBCT reconstruction algorithm to overcome conventional CBCT limitations. By integrating a dual‐source, orthogonal imaging setup, DDCS significantly reduces scanning time and imaging artifacts. A modified Parker‐weighting algorithm further improves image reconstruction accuracy, ensuring high‐fidelity visualization. The goal is to enhance adaptive radiotherapy by improving real‐time patient positioning, dose verification, and motion management. Methods A dual‐detector CBCT system was designed to acquire orthogonal projections simultaneously, reducing scan time and improving data completeness. A modified Parker‐weighting algorithm corrected angular overlap distortions, ensuring better reconstruction accuracy. The system was evaluated using numerical and physical phantom studies to assess spatial resolution, contrast‐to‐noise ratio (CNR), and artifact reduction. Additionally, a dynamic phantom simulated respiratory motion, validating motion robustness for adaptive radiotherapy. Performance was compared against single‐detector CBCT, focusing on image fidelity, noise suppression, and computational efficiency. Results DDCS‐CBCT demonstrated higher CNR, reduced motion artifacts, and improved spatial resolution, leading to more accurate anatomical visualization. The system's efficiency enables faster, more reliable patient setup in IGPT while maintaining a lower imaging dose. Conclusion The proposed DDCS‐CBCT approach significantly improves imaging accuracy, reduces scan time, and enhances real‐time volumetric guidance in IGRT/IGPT. These findings support the clinical feasibility of the DDCS system and its integration into online adaptive radiotherapy workflows.
Atrial arrhythmia associated with cdk4/6 inhibitor use in patients with hormone receptor-positive / HER2-negative breast cancer
Davis, Neil C., Herrmann, Joerg , Hodge, David O. , Blumenfeld, S., Ruddy, Kathryn J. , Tan, Na , Davis, N, Blumenfeld, S, Tan, N

Mayo Clinic

European Heart Journal Supplements | August 1, 2025 | Volume: 27 | Issue: Supplement_6 | Pages: No page available

10.1093/eurheartjsupp/suaf083.042 Get It

Abstract Background Endocrine therapy has been the mainstay treatment for metastatic hormone receptor-positive / HER2-negative (HR+/HER2-) breast cancer. Given that cell cycle dysregulation and consequent uncontrolled cellular proliferation is a key mechanism behind cancer growth, agents targeting this pathway have been of major therapeutic interest.[1] The cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors palbociclib, ribociclib, and abemaciclib have shown a synergistic effect in combination with endocrine therapy.[2-3] Despite favorable results, post-approval studies have revealed potential concerns for cardiotoxicity. [4] Given this, we sought to characterize the incidence and outcomes of atrial arrhythmia among metastatic HR+/HER2- breast cancer patients who were treated with CDK 4/6 inhibitors at our institution. Purpose To investigate the incidence and risk factors of atrial arrhythmia among hormone receptor-positive/HER2-negative breast cancer patients treated with CDK4/6 inhibitors at our institution. Methods A retrospective cohort study was conducted among 2754 patients ≥18 years of age who received treatment with CDK4/6 inhibitors (palbociclib, ribociclib, or abemaciclib) for an established diagnosis of hormone receptor-positive, HER-2 negative breast cancer between 2015-2024. Patients with new onset atrial fibrillation and/or flutter were identified through chart review. The cumulative incidence of new-onset atrial arrhythmia was estimated using the Kaplan-Meier method. Univariable and multivariable Cox regression analyses were performed to identify predictors of atrial arrhythmia. Results A total of 2754 patients was included in the study; 97.3% were female and mean age was 61 years (13). Among these, 101 (3.6%) had a prior history of atrial arrhythmia. The 1-year and 5-year cumulative incidence of new-onset AA were 1.1% and 2.8% respectively (Figure 1). When stratified by specific CDK4/6 inhibitor agents, there was no statistically significant difference. On univariable analysis, age at treatment, hypertension, coronary artery disease, and peripheral vascular disease were associated with new-onset atrial arrhythmia. However, following multivariable adjustment, only age at treatment was statistically significant. Conclusions New-onset atrial arrhythmias may occur during or after CDK4/6 inhibitor use. Older patients appeared to have a higher risk. There were no clear differences in atrial arrhythmia risk between the three CDK4/6 inhibitors.
SGLT2 inhibitors and cardiovascular outcomes in patients with multiple myeloma and concomitant type 2 diabetes mellitus
Tan, Jia Yi , Vignarajah, Aravinthan , Yeo, Yong Hao , Chisti, Mohammad Muhsin , Hilal, Talal , Chan, Kok Hoe , Chisti, Mohammad Muhsin , Hilal, Talal , Yeo, Yong Hao , Chan, Kok Hoe

Mayo Clinic

Leukemia & Lymphoma | July 22, 2025 | Volume: 66 | Issue: 12 | Pages: 2320-2323

10.1080/10428194.2025.2536681 | PMID 40694617 Get It

Baseline predictors of poor clinical outcome despite recanalization of distal middle cerebral artery occlusions
Chafai, Imene , Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Yedavalli, Vivek , Tjoumakaris, Stavropoula , Henninger, Nils , Nedelcu, Simona , Sundararajan, Sri Hari , Kühn, Anna Luisa , Khalife, Jane , Tan, Benjamin Yong‐Qiang , Heit, Jeremy J. , Regenhardt, Robert W. , Puri, Ajit S , Dyzmann, Christian , Filipe, João Pedro , Marotta, Thomas R. , Spears, Julian , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Baker, Amanda , Altschul, David , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Stracke, Christian Paul , Shaikh, Hamza , Liebeskind, David S. , Alexandre, Andrea , Tancredi, Illario , Faizy, Tobias D. , Kalsoum, Erwah , Patel, Aman B. , Wang, Maud , Lubicz, Boris , Guenego, Adrien , ##, On behalf of the MAD MT Investigators, Tjoumakaris, Stavropoula , Ghozy, Sherief , Scarcia, Luca , Tan, Benjamin Yq , Heit, Jeremy J , Regenhardt, Robert W , Cancelliere, Nicole M , Bernstock, Joshua D , Rouchaud, Aymeric , Fiehler, Jens , Sheth, Sunil A , Essibayi, Muhammed Amir , Colasurdo, Marco , Marnat, Gaultier , Renieri, Leonardo , Filipe, João Pedro , Harker, Pablo , Alexandru Radu, Răzvan , Marotta, Thomas R , Spears, Julian , Ota, Takahiro , Mowla, Ashkan , Jabbour, Pascal , Clarençon, Frédéric , Nguyen, Thanh N , Varela, Ricardo , Altschul, David J , Gonzalez, Nestor R , Möhlenbruch, Markus A , Gory, Benjamin , Stracke, Paul , Hecker, Constantin , Shaikh, Hamza A , Liebeskind, David S. , Pedicelli, Alessandro , Alexandre, Andrea M , Tancredi, Illario , Faizy, Tobias D , Kalsoum, Erwah , Fahed, Robert , Wang, Maud , Mendes Pereira, Vitor , Lubicz, Boris , Dmytriw, Adam A , Guenego, Adrien , Kühn, Anna Luisa , Musmar, Basel , Salim, Hamza , Yedavalli, Vivek S , Henninger, Nils , Nedelcu, Simona , Ghozy, Sherief , Cancelliere, Nicole M , Bernstock, Joshua D. , Rouchaud, Aymeric , Fiehler, Jens , Essibayi, Muhammed Amir , Colasurdo, Marco , Renieri, Leonardo , Harker, Pablo , Radu, Răzvan Alexandru , Mowla, Ashkan , Jabbour, Pascal , Nguyen, Thanh N. , Baker, Amanda, Aziz‐Sultan, Mohammad Ali , Hecker, Constantin , Fahed, Robert , Dmytriw, Adam A. , ##, On behalf of the MAD MT Investigators

Mayo Clinic

Interventional Neuroradiology | July 16, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199251342841 | PMID 40665742 Get It

Objective Mechanical thrombectomy (MT) is well-established for the treatment of acute ischemic stroke (AIS) from large vessel occlusion (LVO), with growing data supporting the expansion to distal and medium vessel occlusions (DMVO). Despite successful recanalization in DMVO, certain patients still experience poor long-term clinical outcomes, prompting our study to comprehensively explore pre-MT factors influencing outcome despite excellent recanalization (final modified Thrombolysis in Cerebral Infarction [mTICI] score ≥2c). Methods We retrospectively examined data from patients who consecutively underwent MT for a primary middle cerebral artery (MCA) DMVO across 37 centers in North America, Asia, and Europe. We identified baseline clinical and imaging factors associated with poor clinical outcome (defined as a modified Rankin Scale [mRS] score of 3–6) at 3 months, despite excellent recanalization using a multivariable model. Results Between September 2017 and July 2021, 623 patients achieved mTICI > 2b and they were included in our study. Among them, 198 (32%) experienced a poor clinical outcome (mRS 3–6). Predictors of poor clinical outcome included higher age (OR 1.05 [1.03–1.07], p < 0.001), higher NIHSS at admission (OR 1.12 [1.08–1.15], p < 0.001), higher baseline mRS (OR 1.77 [0.96–3.26], p = 0.067), and diabetes (OR 1.59 [1.01–2.48], p = 0.044). Higher ASPECTS was associated with a decreased risk of poor clinical outcome (OR 0.82 [0.71–0.94], p = 0.006). Conclusion Older age, diabetes, higher baseline mRS, and NIHSS were associated with poor clinical outcome in MCA DMVO despite excellent recanalization. Conversely, a higher ASPECTS decreased the probability of such an outcome.
Petechial hemorrhage in mechanical thrombectomy for distal and medium-vessel occlusions: technical considerations and outcomes
Baker, Amanda , Adeeb, Nimer , Henninger, Nils , Sundararajan, Sri Hari , Khalife, Jane, Tan, Benjamin Yong‐Qiang , Regenhardt, Robert W. , Heit, Jeremy J. , Cancelliere, Nicole M., Fiehler, Jens, Puri, Ajit S., Dyzmann, Christian , Colasurdo, Marco, Filipe, João Pedro , Harker, Pablo, Abdalkader, Mohamad , Marotta, Thomas R. , Spears, Julian , Jabbour, Pascal , Biswas, Arundhati , Clarençon, Frédéric , Varela, Ricardo , Gonzalez, Nestor R. , Möhlenbruch, Markus , Costalat, Vincent , Gory, Benjamin , Yedavalli, Vivek , Stracke, Christian Paul , Shaikh, Hamza, Liebeskind, David S., Alexandre, Andrea , Faizy, Tobias D., Tancredi, Illario , Kalsoum, Erwah , Lubicz, Boris , Patel, Aman B. , Guenego, Adrien , Altschul, David , _, _, Amllay, Abdelaziz, Gopinathan, Anil, Dusart, Anne , Capirossi, Carolina , Mounayer, Charbel, Hsieh, Cheng-Yang, Stapleton, Christopher J. , Bellante, Flavio, Shaikh, Hamza , Cuellar-Saenz, Hugo H., Rabinov, James D. , Berge, Jérôme , Martinez-Gutierrez, Juan Carlos, Premat, Kévin , Chervak, Lina , Elhorany, Mahmoud, Quintero‐Consuegra, Miguel , Kan, Peter , Khandelwal, Priyank , Kadirvel, Ramanathan , Dofuku, Shogo , Nedelcu, Simona, Tjoumakaris, Stavropoula I, Barreau, Xavier, Liebeskind, David S. , Liebeskind, David S. , Heit, Jeremy J , Altschul, David J , Gonzalez, Nestor R , Regenhardt, Robert W , Yedavalli, Vivek S , Henninger, Nils , Tan, Benjamin Yq , Alexandre, Andrea M , Varela, Ricardo , Essibayi, Muhammed Amir , Salim, Hamza , Fazzari, Melissa J. , Khatri, Deepak , Baker, Amanda, Musmar, Basel , Kühn, Anna Luisa , Khalife, Jane , Ghozy, Sherief , Scarcia, Luca , Yeo, Leonard Ll , Cancelliere, Nicole M , Rouchaud, Aymeric , Sheth, Sunil A , Puri, Ajit S , Colasurdo, Marco , Renieri, Leonardo , Harker, Pablo , Aziz, Yasmin , Radu, Răzvan Alexandru , Klein, Piers , Ota, Takahiro , Mowla, Ashkan , Naamani, Kareem El , Jabbour, Pascal , Siegler, James E. , Nguyen, Thanh N. , Gory, Benjamin , Hecker, Constantin , Marnat, Gaultier , Griessenauer, Christoph J. , Pedicelli, Alessandro , Faizy, Tobias D. , Mendes Pereira, Vitor , Dmytriw, Adam A. , _, _, Amllay, Abdelaziz , Vagal, Achala , Schiphorst, Adrien ter , Thomas, Ajith J , Mounayer, Charbel , Weyland, Charlotte S. , Hsieh, Cheng‐Yang , Forestier, Géraud , Cuellar, Hugo , Valente, Iacopo , Sibon, Igor , Jesser, Jessica , Martinez-Gutierrez, Juan Carlos , Meyer, Lukas , Elhorany, Mahmoud , Aziz‐Sultan, Mohammad Ali , Killer-Oberpfalzer, Monika , Khandelwal, Priyank , Fahed, Robert , Salazar‐Marioni, Sergio , Nedelcu, Simona , Tjoumakaris, Stavropoula , Saleme, Suzana , Barreau, Xavier

Mayo Clinic

Journal of Neurosurgery | July 4, 2025 | Volume: 143 | Issue: 6 | Pages: 1501-1513

10.3171/2025.3.jns243030 | PMID 40614268 Get It

OBJECTIVE Mechanical thrombectomy (MT) is well established for large-vessel occlusion (LVO) strokes, but its safety in distal and medium-vessel occlusions (DMVOs) requires further investigation. This study analyzed the relationship between procedural approaches, petechial hemorrhage (PetH), and clinical outcomes in DMVO thrombectomy, with particular attention to technical considerations and the complex interplay between tissue injury and hemorrhagic complications. METHODS A retrospective cohort study was conducted on DMVO stroke patients treated with MT at 37 stroke centers worldwide from 2016 to 2024. Patients were categorized based on follow-up imaging into those with or without PetH. Four logistic regression models analyzed the association of PetH with favorable functional outcomes (modified Rankin Scale score ≤ 2) at 90 days, early neurological improvement (≥ 4-point National Institutes of Health Stroke Scale score decrease at 24 hours), all-cause mortality, and independent determinants of PetH. Adjusted odds ratios (aORs), 95% confidence intervals, and p values were reported. RESULTS Of 1428 patients, 439 (30.7%) developed PetH. Factors independently associated with PetH were multiple thrombectomy passes (aOR 1.58, 95% CI 1.21–2.06; p = 0.001), IV thrombolysis (aOR 1.31, 95% CI 1.01–1.69; p = 0.04), and the combined use of a stent retriever with aspiration as the first-line method compared with aspiration alone (aOR 1.66, 95% CI 1.15–2.38; p = 0.007). Conversely, general anesthesia (aOR 0.55, 95% CI 0.40–0.77; p < 0.001), higher Alberta Stroke Program Early CT Scores (aOR 0.76, 95% CI 0.69–0.83; p < 0.001), and successful recanalization (aOR 0.56, 95% CI 0.39–0.80; p = 0.002) were significantly associated with a lower odds of PetH. PetH was associated with a decreased odds of favorable functional outcomes (aOR 0.51, 95% CI 0.36–0.73; p < 0.001), reduced early neurological improvement (aOR 0.59, 95% CI 0.44–0.79; p < 0.001), and increased all-cause mortality (aOR 1.84, 95% CI 1.23–2.76; p < 0.001). CONCLUSIONS PetH is a frequent sequela following MT in DMVO strokes and is associated with poorer outcomes, likely reflecting underlying ischemic injury rather than direct causation. Procedural factors influence PetH risk, suggesting medical treatment as first-line therapy for DMVOs, with MT reserved for refractory cases using less aggressive approaches.
Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma
Liu, Matthew , Steen, Sanna , Tsiknakis, Nikolaos, Vidal, Joan Martínez , Maher, Nigel G. , Tan, Samuel , Bai, Yalai , Wong, Pok Fai , Gavirelatou, Niki, He, Mengni , Barna, Robert , Bosić, Martina , Bräutigam, Konstantin , Chenhao, Zhou, Gama, João Martins , Kreis, Bianca, Mohácsi, Réka , Pillar, Nir , Poulios, Christos , Toli, Maria Angeliki , Tzoras, Evangelos , Bracero, Yadriel , Bosisio, Francesca M. , Fortarezza, Francesco , Gonzalez, Mercedes Solorzano, Gullo, Irene , Gutiérrez, Francisco Javier Queipo , Hacıhasanoğlu, Ezgi , Jović, Viktor , Lazar, Bianca Andreea, Neppl, Christina, Pinto, Daniel , Plótár, Vanda, Rau, Tilman T. , Skok, Kristijan , Sun, Wenwen , Solaß, Wiebke , Szymoński, K , Thimm, Franziska , Vignati, Danielle, Vigdorovits, Alon , Prieto, Víctor G. , Sinnberg, Tobias , Wilmott, James S. , Cowper, Shawn E. , Hartman, Johan , Osman, Iman , Ács, Balázs , Nourmohammadi, Saeed, Acs, Balazs , Hartman, Johan , Aung, Thazin Nwe , Su, David , Shafi, Saba , Boyacı, Ceren , Tsiknakis, Nikos , Micevic, Goran , Vesely, Matthew D. , Nourmohammadi, Saeed , Djureinovic, Dijana , Bates, Katherine, Chan, Nay Nwe Nyein , Burela, Sneha , Illa-Bochaca, Irineu , Kreis, Bianca, Pinto, João Correia , Cserni, Gábor , Dema, Alis Liliana Carmen , Gonzalez, Mercedes Solorzano, Olincă, Maria , Oliveira, Rui Caetano , Pezzuto, Federica , Pop, Ovidiu Laurean , Serbes, Ezgi Dicle , Stanowska, Olga , Szász, Attila Marcell , Warrell, Jonathan , Saenger, Yvonne M. , Plummer, Jasmine , Rimm, David L.

Mayo Clinic

JAMA Network Open | July 3, 2025 | Volume: 8 | Issue: 7 | Pages: e2518906

10.1001/jamanetworkopen.2025.18906 | PMID 40608341 Get It

Importance Tumor-infiltrating lymphocytes (TILs) are a provocative biomarker in melanoma, influencing diagnosis, prognosis, and immunotherapy outcomes; however, traditional pathologist-read TIL assessment on hematoxylin and eosin–stained slides is prone to interobserver variability, leading to inconsistent clinical decisions. Therefore, development of newer TIL scoring approaches that produce more reliable and consistent readouts is important. Objective To evaluate the analytical and clinical validity of a machine learning algorithm for TIL quantification in melanoma compared with traditional pathologist-read methods. Design, Setting, and Participants This multioperator, global, multi-institutional prognostic study compared TIL scoring reproducibility between traditional pathologist-read methods and an artificial intelligence (AI)-driven approach. The study was conducted using retrospective cohorts of patients with melanoma between January 2022 and June 2023 across 45 institutions, with tissue evaluated by participants from academic, clinical, and research institutions. Participants were selected to ensure diverse expertise and professional backgrounds. Main Outcomes and Measures Intraclass correlation coefficient (ICC) values were calculated for the manual and AI-assisted arms using log-transformed data. Kendall W values were calculated for Clark scores (brisk = 3, nonbrisk = 2, and sparse = 1). Reliabilities of ICC and W values were classified as moderate (0.40-0.60), good (0.61-0.80), or excellent (&amp;gt;0.80). AI TIL measurements were dichotomized using the 16.6 and median cutoffs. Univariable and multivariable Cox regression analyses assessed the prognostic value of TIL scores adjusted for clinicopathologic variables. Results There were 111 patients with melanoma in the independent testing cohort (median [range] age at diagnosis, 61.0 [25.0-87.0] years; 56 [50.5%] male) who contributed melanoma whole tissue sections. A total of 98 participants evaluated TILs on 60 hematoxylin and eosin–stained melanoma tissue sections. All 40 participants in the manual arm were pathologists, while the AI-assisted arm included 11 pathologists and 47 nonpathologists (scientists). The AI algorithm demonstrated superior reproducibility, with ICCs higher than 0.90 for all machine learning TIL variables, significantly outperforming manual assessments (ICC, 0.61 for AI-derived stromal TILs vs Kendall W , 0.44 for manual Clark TIL scoring). AI-based TIL scores showed prognostic associations with patient outcomes (n = 111) using the median cutoff approach with a hazard ratio (HR) of 0.45 (95% CI, 0.26-0.80; P = .005), and using the cutoff of 16.6, with an HR of 0.56 (95% CI, 0.32-0.98; P = .04). Conclusions and Relevance In this prognostic study of TIL quantification in melanoma, the AI algorithm demonstrated superior reproducibility and prognostic associations compared with traditional methods. Although the retrospective nature of the cohorts limits demonstration of clinical utility, the publicly available dataset and open-source AI tool offer a foundation for future validation and integration into melanoma management.
Advancements in Visual Field Testing: A Systematic Review of the 24-2C Test Grid
Jin, Eric , Wong, Natalie Shi Qi , Goh, Claire Xin Yi, Stewart, Michael W., Dorairaj, Syril, Ang, Bryan Chin Hou , Ang, Bryan C H , Dorairaj, Syril

Mayo Clinic

Bioengineering | July 1, 2025 | Volume: 12 | Issue: 7 | Pages: 711

10.3390/bioengineering12070711 | PMID 40722403 Get It

A systematic review was conducted of studies published up to 30 August 2024. Studies comparing conventional visual field (VF) indices, ability to detect central visual field defects (CVFDs), structure–function (S-F) concordance, and test characteristics across the HVF 24-2C SITA-Faster, 24-2 SITA-Standard/Faster, and 10-2 SITA-Standard/Fast tests were included. Eight studies with 1239 subjects (49.1% male; mean age, 54.8–66.9 years) were analyzed. The 24-2C produced similar global VF indices compared to the 10-2 and 24-2 (Standard/Faster) (ICC = 0.95 and 0.80, p < 0.001), detected more VF defects and CVFD clusters, and demonstrated greater S-F concordance than the 24-2 (Standard/Faster). Although the 10-2 (Standard/Fast) detected significantly more CVFDs and had a greater S-F concordance, the agreement between the 24-2C and 10-2 grids was substantial (ĸ = 0.488 to 0.708). The 24-2C was also faster compared to the 24-2 Standard and 10-2 (Standard/Fast), with comparable false positives, higher false negatives, and fewer fixation losses than the 24-2 Standard. In conclusion, the HVF 24-2C is quicker and identifies more CVFDs than the 24-2 grid, demonstrates high agreement with the 10-2 grid, and aids in CVFD screening.